Caleo Biotechnologies Inc.

Fibrotic and inflammatory diseases stem from complex interactions across epithelial, stromal, and immune cells. Yet most preclinical models such as animal systems and conventional organoids fail to capture this multicellular interplay or the heterogeneity driving disease progression. This disconnect leads to poor predictive accuracy and high failure rates in late-stage clinical trials. At CaleoBio, we’re advancing next-generation, patient-derived Organ-Dish (OD) models that move beyond reductionist systems. ODs are self-organizing models that recapitulate native tissue structure and function.